Cutler 2004 — Are the Benefits of Medicine Worth What We Pay for It

Summary

Cutler asks whether the growth in U.S. medical spending since 1950 has generated sufficient health value to justify its cost, and answers yes. Using the value of statistical life (VSL) framework to convert life-year gains into dollar-equivalent benefits, he shows that the aggregate health improvements attributable to medical innovation — especially cardiovascular treatment — substantially exceed the aggregate increase in medical spending. The paper is a synthesis of Cutler's broader research program on the economics of medical innovation and serves as the analytical backbone of his contemporaneous book Your Money or Your Life (Oxford, 2004).

Key Claims

• Medical spending growth: U.S. healthcare spending has grown from roughly $\$700$/person in 1950 to over $\$6{,}000$/person by 2004 (real), growing at $2$–$3$ percentage points (pp) above general inflation.
• Life expectancy gains: Life expectancy (LE) at birth rose from approximately $68$ years (1950) to $77$ years (2000); most of the post-1960 gain is attributable to reductions in cardiovascular mortality.
• Attribution to medicine: Cutler argues that medical innovation — drugs, devices, and procedures — accounts for roughly half of the post-1960 improvement in life expectancy; the remainder reflects behavioral changes (declining smoking) and public health.
• VSL framework: A life-year is worth approximately $\$100{,}000$–$\$200{,}000$ based on compensating-wage differentials and contingent valuation studies (following Rosen 1988; Murphy and Topel 2006); each additional year of life expectancy at the population scale generates roughly $\$2.4$ trillion in willingness-to-pay (WTP)-based social value.
• Heart disease case study: The cost of improved acute myocardial infarction (MI) care (thrombolytics, angioplasty, bypass surgery) per life-year gained is approximately $\$10{,}000$–$\$30{,}000$ — well below the $\$100{,}000$ threshold. On this dimension, medicine is highly cost-effective.
• Neonatal case study: Intensive care for very low birth weight infants is more expensive per life-year ($\approx \$60{,}000$–$\$80{,}000$) but remains within standard willingness-to-pay bounds.
• Aggregate benefit-cost: The total dollar value of health improvements since 1950 (using VSL-weighted life-year gains) substantially exceeds the total cumulative growth in medical expenditure; the return on medical investment is positive in aggregate.
• Why spending is high: High U.S. spending reflects not primarily waste but first-adopter premiums on medical innovation — other countries free-ride on U.S. technology diffusion while paying regulated prices.
• Implication: The policy problem is not whether to spend on medicine but how to direct spending toward high-value innovations and away from cost-ineffective care.

Concepts Introduced or Extended

• Value of Medical Innovation — VSL-based cost-benefit framework for evaluating aggregate medical spending; shows health gains exceed spending growth

Entities Mentioned

• David Cutler

Quotes

"The issue is not whether medical care is worth what we pay for it — in the aggregate, it clearly is. The issue is whether we are spending on the right things."

"Each year of life is worth about $100,000 to the average American. With that benchmark, the returns to medical care easily justify its costs."

My Take

The paper's central move — converting life-year gains to dollars using VSL, then comparing to spending growth — is methodologically defensible but depends critically on the VSL estimate and the attribution fraction (how much of LE gains go to medicine vs. behavior). Cutler's $\approx 50\%$ attribution is contested; others (Ford et al. 2007) attribute more of the cardiovascular disease (CVD) decline to risk factor changes (especially cholesterol and smoking reduction) than to treatment. The aggregation also masks enormous heterogeneity: some medical spending (preventive care, some surgical interventions) is far above the cost-effectiveness threshold, and some (end-of-life intensive care, many brand-name drugs) is far below it. The paper is most useful as a corrective to the naive view that rising medical spending is pure waste, establishing that a significant fraction creates genuine welfare gains. The argument was influential in subsequent debates about healthcare cost control: it shifted the policy question from "spend less" to "spend better."